CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
GRF6021 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03713957
NCT03713957Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Alkahest, Inc.·interventional·Posted Oct 22, 2018·Updated May 9, 2022

In Brief

A Phase 2 clinical trial evaluating GRF6021 and Placebo for Parkinson Disease. Completed, enrolled 79 participants across 29 sites in 3 countries.

Detailed Summary

This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesAustralia, France, United States
CollaboratorsMichael J. Fox Foundation for Parkinson's Research

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 22, 2018
Enrollment StartNov 12, 2018
Primary CompletionJul 20, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.7 years ago

Interventions

GRF6021drug

GRF6021 for IV infusion

Placeboother

Placebo for IV infusion